Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that a subsidiary has entered into a supply agreement with Ortho-McNeil, Inc., a Johnson & Johnson company, for the marketing and distribution of a once-daily, extended-release (ER) formulation and an orally disintegrating (ODT), immediate-release formulation of tramadol hydrochloride in the United States and Puerto Rico. Ortho-McNeil has retained an option for Ultram(R) ER for other jurisdictions, excluding Canada and Europe. The agreement is subject to Hart-Scott-Rodino regulatory clearance in the United States.
